Suggested remit: To appraise the clinical and cost effectiveness of sacituzumab govitecan within its marketing authorisation for treating hormone receptor-positive HER2-negative metastatic breast cancer after 2 or more therapies.
The company has informed NICE that it will not provide an evidence submission for this appraisal. Therefore, we are suspending the appraisal while we consider the next steps.
- Status:
- Suspended
- Technology type:
- Medicine
- Decision:
- Selected
- Process:
- STA Standard
- ID number:
- 4033
Email enquiries
If you have any queries please email [email protected]
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 30 July 2025 | Suspended. The company has informed NICE that it will not provide an evidence submission for this appraisal. Therefore, we are suspending the appraisal while we consider the next steps. |
| 21 November 2022 | As you will be aware the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of Sacituzumab govitecan within its marketing authorisation for treating hormone receptor-positive HER2-negative metastatic breast cancer after 2 or more therapies. Please note that following on from advice received from the company the timelines for this appraisal are to be confirmed. The appraisal will be rescheduled to align with latest regulatory expectations and an update on the revised timelines will be provided when further information is available. |
| 09 June 2022 - 07 July 2022 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 28 January 2022 | In progress. DHSC referral received |
For further information on our processes and methods, please see our CHTE processes and methods manual